Myeloma Minute: New Year, New Myeloma Drugs, New Question
December 17, 2015
Three Holiday Presents for Myeloma Patients
With the recent FDA approvals of the myeloma drugs Darzalex (daratumumab), Ninlaro (ixazomib) and Empliciti (elotuzamab), the end of 2015 offered many holiday presents for myeloma patients. But, as IMF Chairman Dr. Brian Durie writes in his blog this week, in the New Year, myeloma doctors will need to figure out how to use these drugs in a clinical setting. To read Dr. Durie’s blog, click HERE.
Shop for the IMF!
Shop with the leading merchants on the Internet, receive the same price as anyone else visiting their sites, and support the IMF at the same time! Visit popular merchants such as Amazon, Walmart, and others, and a percentage of your purchase goes to support the IMF. Please remember that the IMF receives a donation ONLY IF YOU VISIT THE IMF ONLINE MALL and purchase from the links listed on this page. You may want to bookmark this page to ensure that when you are shopping, your purchases are properly credited. And keep checking back as we add new stores to our Mall. Thanks for your support!
Free Best of ASH 2015 Teleconference
Now that the American Society of Hematology’s (ASH) 2015 annual meeting has come to a close, attendees are sorting through the breadth of knowledge, research, and educational information shared. To simplify the latest trends in myeloma research, the IMF will present a free teleconference: “The Best of ASH 2015: What Patients & Caregivers Need to Know.”Dr. Brian Durie will host this ninety-minute session onThursday, January 7, 2016, at 4 PM PT / 7 PM ET. If you tune into the teleconference, you will also have a chance to participate—30 minutes of this teleconference will feature a question and answer session with Dr. Durie. To watch the replay, click HERE.
And That's a Wrap: Myeloma Support Group Leaders' Final Thoughts on ASH 2015
The IMF sent 15 Support Group Leaders (SGLs) from around the country to the largest hematological cancer meeting of the year in Orlando, FL, in early December. While attending, the SGLs blogged and tweeted the latest news in myeloma research. Now that they have returned to their hometowns, these patient advocates weigh in on ASH topics most important to them: when to treat smoldering multiple myeloma; the newly approved FDA oral agents in individual treatments; MRD-testing; and more. To read these wrap-up blogs, click HERE.
We Would Like to Thank Our Sponsors: Takeda, Celgene, Amgen, and Bristol-Myers Squibb